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Abstract
Objective: The purpose of the study was to compare early changes in blood flow (BF) and glucose
metabolism (MRglu) in metastatic breast cancer lesions of patients treated with chemotherapy.
Methods: Eleven women with stage IV cancer and lesions in breast, lymph nodes, liver, and
bone were scanned before treatment and after the first course of chemotherapy. BF, distribution
volume of water (Vd), MRglu/BF ratio, MRglu and its corresponding rate constants K1 and k3 were
compared per tumor lesion before and during therapy.
Results: At baseline, mean BF and MRglu varied among different tumor lesions, but mean Vd
was comparable in all lesions. After one course of chemotherapy, mean MRglu decreased in all
lesions. Mean BF decreased in breast and node lesions and increased in bone lesions. Vd
decreased in breast and nodes, but did not change in bone lesions. The MRglu/BF ratio
decreased in breast and bone lesions and increased in node lesions. In patients with multiple
tumor lesions BF and MRglu response could be very heterogeneous, even within similar types of
metastases. BF and MRglu increased in lesions of patients who experienced early disease
progression or showed no response during clinical follow-up.
Conclusion: BF and MRglu changes separately give unique information on different aspects of
tumor response to chemotherapy. Changes in BF and MRglu parameters can be remarkably
heterogeneous in patients with multiple lesions.
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Introduction
Stage IV breast cancer is considered incurable. Treatmentis directed towards palliation of symptoms and disease
stabilization, and with the use of polychemotherapy and
taxanes, overall survival can be prolonged [1–2]. Conven-
tionally, clinical response is evaluated after several cycles of
chemotherapy by monitoring changes in tumor dimension as
determined by physical examination and (anatomical) imag-
ing techniques. There are certain tumor-specific character-
istics that play a role in responsiveness to therapy. For
example, high glucose metabolism and high degree of (neo)
vascularization correlate with poor prognosis, and vascular-
ization and perfusion are important factors in growth andCorrespondence to: Nanda Krak; e-mail: n.krak@erasmusmc.nl
metastasizing potential of breast tumors [3–5]. On the other
hand, poor tumor perfusion may hamper delivery of
intravenous therapy and may lead to hypoxia, which is
known to contribute to resistance to standard radiotherapy
and chemotherapy and is associated with poor prognosis [6–
7]. Overall clinical response rates following chemotherapy, as
measured conventionally, vary between 20% and 80%,
depending on the (combination of) agent used [2, 8]. This
means that many patients are exposed to the morbidity, side
effects, and costs of ineffective therapy. There is evidence that
measurement of metabolic changes using positron emission
tomography (PET) might be a sensitive method to assess early
response to treatment [9–13]. The ultimate goal of using PET
would be to guide effective treatment to responders, while
avoiding unnecessary side effects in nonresponders.
To date, most PET studies in breast cancer assessing
response have involved patients with locally advanced breast
cancer (LABC) [9–15], and only a few focused on metastatic
breast cancer [16–18]. The change emphasizes response
assessment. At present, the most commonly used tracer in
response monitoring studies is the glucose analogue 2-
deoxy-2-[F-18]fluoro-D-glucose (FDG), which measures
glucose metabolism. An alternative approach is to measure
tumor perfusion in vivo using H2
15O, a freely diffusible,
metabolically inert tracer [18]. Both FDG and H2
15O could
provide, either by themselves or combined, better insight
into tumor behavior both prior to and during chemotherapy,
e.g., by identifying factors that may play a role in
responsiveness [13, 14, 19].
Thus, the primary aim of this pilot study was to compare
early changes in blood flow (BF) and glucose metabolism
(MRglu) in metastatic breast cancer lesions of patients treated
with chemotherapy.
Materials and Methods
Patients
Eleven patients with stage IV breast cancer who were scheduled to
receive chemotherapy were included in this study. Mean age±SD
was 55±9 years (range 42–72 years). All patients had an Eastern
Cooperative Oncology Group (ECOG) performance status ranging
from 0–2. Metastases were at least 2 cm in diameter and located
sufficiently near the heart to make use of an image-derived arterial
input function. Metastases were biopsy proven or diagnosed by
appropriate image modalities (bone scan, abdominal ultrasound, or
abdominal CT). Bone metastases were characterized as lytic,
blastic, or mixed based on their appearance on X-ray or CT.
Exclusion criteria were pregnancy, diabetes, claustrophobia, and
chemotherapy within 6 weeks prior to the study. In addition, bone
lesions that had received prior selective radiotherapy were excluded
as reference lesions.
PET scans were performed within 5 days before the first and
second course of chemotherapy, respectively. Regimens included
FAC (5-fluorouracil 500 mg/m2, cyclophosphamid 500 mg/m2, and
doxorubicin 50 mg/m2 3-weekly), Doc (docetaxel 100 mg/m2 3-
weekly), AT (doxorubicin 50 mg/m2 and docetaxel 100 mg/m2 3-
weekly), CAT (cisplatinum 50 mg/m2, doxorubicin 50 mg/m2,
paclitaxel 100 mg/m2 3-weekly), and Vinorelbine (25 mg/m2
weekly). The Medical Ethics Committees of the VU University
Medical Centre and Amstelland Hospital approved the study.
Tumor Response and Clinical Follow-Up
Referring physicians were blinded to results of the second PET
scan. After the second PET scan, patients returned to regular
follow-up with their treating physician. Clinical endpoint was time
to progression (TTP). Disease progression was defined by the
treating physician, as directed by symptoms, blood tests, and/or
physical examination during follow-up using appropriate imaging
modalities, i.e., ultrasound or CT for liver lesions and bone scan,
CT, or MRI for bone lesions. Progression of lymph nodes and liver
metastases was defined by the RECIST criteria [20]. For bone
metastases, any increase in size of known metastases or the
appearance of new metastases was interpreted as progression.
Acquisition Protocol and Image Processing
All PET scans were performed on an ECAT EXACT HR+ scanner
(Siemens/CTI, Knoxville, TN, USA), which consists of 32 rings of
bismuth germinate crystal detectors and has a 15.5-cm axial field of
view. Patients fasted for at least 6 h prior to scanning. Following a
10-min transmission scan to correct the subsequent emission scans
for photon attenuation, 1,100 MBq of H2
15O was injected
intravenously, simultaneously starting a 10-min dynamic emission
scan (12×5 s, 12×10 s, 6×20 s and 10×30 s frames). Next, a
second dynamic emission scan with a total duration of 60.5 min
(1×30 s, 6×5 s, 6×10 s, 3×20 s, 5×30 s, 5×60 s, 8×150 s, 6×
300 s frames) was started, with an intravenous injection of
370 MBq of FDG at the start of the second frame. The 30 s
background frame was used to correct for any residual 15O activity
remaining from the H2
15O scan. All data were acquired in 2D
mode. During the FDG scan venous samples were collected at 35,
45, and 55 min postinjection for measurement of plasma glucose
and for quality control of the image-derived input function [21]. All
PET data were corrected for decay, dead time, scatter, random
coincidences, and measured photon attenuation. All scans were
reconstructed as 128×128 matrices using filtered back projection
(FBP) with a 0.5 Hanning filter, resulting in a transaxial spatial
resolution of ∼7 mm in the centre of the field of view. For
definition of tumor regions of interest (ROIs), summed images of
the FDG scan and H2
15O scan were reconstructed using ordered
subset expectation maximization (OSEM), which was followed by
5 mm Gaussian smoothing, resulting in the same transaxial spatial
resolution as for the FBP images [22].
PET Data Analysis
Arterial input curves were derived from 15 mm ROIs placed over
the aorta, left atrium, and left ventricle [23], using the FBP images
of the fourth and fifth frames for the FDG scan [24] and the first 12
frames for the H2
15O scan [25].
All tumor ROIs were defined on OSEM reconstructed images of
the FDG scan. These ROIs were used to generate time–activity
curves from the dynamic frames of both the FDG and H2
15O scans.
ROIs were drawn using a semiautomatic region-growing method,
including only pixels with a cutoff of 75% of the maximum activity
within a lesion [26].
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For H2
15O, the standard single-tissue compartment model was
used [18]. Blood flow (BF) was not calculated for liver lesions
because estimates using the single-tissue compartment model may
not be reliable for the liver [27]. Fitting was performed both with
and without an arterial blood volume component, and the best fit
was determined by Akaike and Schwarz criteria, as described
previously [24].
For FDG, Patlak graphical analysis [28] with an acquisition
interval of 10–60 min p.i. was used to calculate glucose metabolism
(MRglu). The two-tissue compartment model with three rate
constants [24, 29] was used in addition, in order to acquire more
detailed information on delivery (K1) and phosphorylation (k3) of
FDG.
Finally, the MRglu to BF ratio was calculated, a metabolic
parameter introduced by Mankoff et al. as an indirect indicator of
glucose use relative to glucose delivery and used as a predictor of
macroscopic complete response [13]. This ratio is proportional to
K1/BF (= glucose extraction fraction)×k3/(k2+k3)·
Statistics
For all lesions, mean±standard deviation (SD) was calculated for
MRglu, rate constants K1 and k3, BF, Vd, and MRglu/BF before
treatment and after one course of chemotherapy. Differences in
parameters before and after chemotherapy were tested for signifi-
cance using the two-tailed Student t-test. Pearson correlation
coefficients were estimated between BF and MRglu, between BF,
K1, and k3, and between the MRglu/BF ratio, K1 and k3, both before
and during treatment. Multilevel analysis was performed to correct
for multiple lesions within the same patient. A p valueG0.05 was
considered statistically significant.
Results
Baseline
All patients were scanned twice (at baseline and after one
course of therapy) with FDG and H2
15O, with the exception of
one patient for whom H2
15O was not available on the second
scan for technical reasons. The same number of lesions was
identified on the FDG and H2
15O scans. Uptake was adequate
(moderate to high) in baseline lesions, so no conventional
imaging was necessary to help identify these lesions. On the
baseline scans, 45 measurable lesions were found: eight breast
tumors, 17 lymph nodes, 15 bone, and five liver metastases.
Lymph node metastases included axillary and supraclavicular
nodes. The median follow-up period was 13 months. Patient
characteristics are summarized in Table 1.
BaselineMRglu in normal breast was 0.01±0.004 μmol·ml
−1·-
min−1 vs. 0.11±0.07 μmol·ml−1·min−1 in breast tumors (pG
0.03). MRglu was comparable in breast tumors and lymph
node metastases, and higher in bone and liver metastases
(Table 2). BF and Vd values used in this study were
estimated without an arterial blood volume component, as
both Akaike and Schwarz criteria indicated that inclusion of
arterial blood volume did not significantly improve the
quality of the fits. Normal breast had a mean baseline BF of
0.04±0.03 vs. 0.43±0.23 ml·ml−1·min−1 in breast tumors
(pG0.02). Mean BF was highest in node metastases (0.60±
0.27 ml·ml−1·min−1) and lowest in bone lesions (0.41±
0.24 ml·ml−1·min−1). Vd was 0.13±0.06 ml·ml
−1 in normal
breast tissue. Vd values in breast lesions were similar to
those in nodal and bone lesions. The MRglu/BF ratio was
lowest in node lesions (0.23±0.15), followed by breast
tumors (0.31±0.19) and bone lesions (0.41±0.29).
Chemotherapy-Induced Changes
The same 45 baseline lesions were identified on the FDG
scans after one course of therapy. One patient with bilateral
breast lesions and ten node metastases could only be scanned
with FDG the second time, however, so 33 lesions were
evaluable on the post-therapy H2
15O scans of ten women: six
breast tumors, seven lymph nodes, 15 bone, and five liver
metastases.
After one cycle of chemotherapy, mean MRglu decreased
in all lesions. Compared with baseline, these reductions were
statistically significant for breast tumors, nodes, and bone
lesions and of borderline significance for liver lesions (see
Table 2).
Mean BF decreased in all lesions except bone metastases
(Table 2 and Fig. 1a). Mean Vd decreased in breast tumors
Table 1. Patient characteristics
Patient no. Age Histology Tumor lesions Therapy TTP (months) TTD (months)
1 72 Ductal Bone (lytic) FAC 6 9
2 42 Lobular Liver Vino 11 14
3 47 Ductal Supraclavicular nodes Doc 2 2
4 42 Adeno Liver Doc 5 20
5 53 Lobular Breasta, axillary nodes AT 4 5
6 58 Adeno Breast, bone (mixed) CAT NER NER
7 65 Lobular Breastb, supraclavicular nodes FAC 5 6
8 55 Lobular Breast, axillary nodes, bone (mixed) Vino 4 26
9 59 Adeno Breast, cervical nodes, bone (sclerotic) FAC 12 24
10 49 Ductal Breast, axillary nodes, bone (lytic), liver Doc 4 13
11 58 Ductal bone (mixed) FAC 9 13
TTP Time to progression, TTD time till death, NER no evidence of recurrence, ductal ductal carcinoma, lobular lobular carcinoma, adeno adenocarcinoma,
FAC 5-fluorouracil, cyclophosphamid, doxorubicin, Doc docetaxel, AT doxorubicin, docetaxel, CAT cisplatinum, doxorubicin, paclitaxel, Vino Vinorelbine
aMultifocal tumor
bBilateral tumor
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and nodes and remained unchanged in bone lesions
(Fig. 1b). Compared with baseline, however, changes in
BF and Vd were not statistically significant (Table 2).
There was an increase in K1 in breast tumors and bone
lesions and a decrease in nodes and liver lesions, while k3
decreased in all lesions. Except for the decrease in k3 in
breast lesions (pG0.05), changes in K1 and k3 were not
statistically significant in other lesions.
Changes in the MRglu/BF ratio were only significant for
bone lesions (pG0.05), although they approached signifi-
cance for breast tumors (p=0.06).
Correlation Between Parameters
Correlation between baseline MRglu and BF was moderate for
breast lesions (r=0.79, Fig. 2 and Table 3), and even lower for
nodes and bone metastases (r=0.64 and 0.49, respectively).
Excluding the 12 lesions from the patient with bilateral breast
lesions and ten node metastases that did not receive the
second H2
15O scan from the baseline, analysis resulted in only
moderately lower correlation values (r=0.76 and r=0.51 for
breast and nodes, respectively). After therapy, correlation
between MRglu and BF improved dramatically for breast
lesions (r=0.98), but remained similar for nodes and bone
metastases (r=0.62 and r=0.50, respectively).
At baseline, correlation between BF and K1 or BF and k3
was weak to moderate for breast lesions (r=0.43 and r=0.58,
respectively), but after chemotherapy, there was a significant
improvement in correlation (r=0.86, pG0.03 and r=0.94, pG
0.005, respectively). In contrast, in bone lesions, correlation
between BF and K1 was similar before and after therapy (r=
0.62 and r=0.59, respectively), while the modest baseline
correlation between BF and k3 (r=0.52) was lost after therapy
(r=0.15). Because of the small number of lymph nodes after
therapy, changes in correlation between BF and MRglu
parameters should be viewed with caution (see Table 3).
Inter-lesion Heterogeneity
Changes in BF and MRglu after the first course of
chemotherapy were often remarkably heterogeneous within
one patient, not only between different types of lesions, but
even within similar lesions. Fig. 3 shows examples of typical
heterogeneous response in two patients with multiple
lesions. Similarly, heterogeneous response was observed in
patient nos. 6, 8, and 10.
Table 2. PET parameters before and after one course of chemotherapy for normal breast and tumor lesions
Parameter Baseline mean (±SD) After 1× CTh mean (±SD) p
MRglu (μmol/ml/min)
Normal breast 0.01±0.004 0.01±0.004 0.97
Breast tumor 0.11±0.07 0.07±0.04 0.002
Nodes 0.11±0.04 0.06±0.06 G0.001
Bone metastases 0.15±0.10 0.12±0.09 0.003
Liver metastases 0.19±0.09 0.11±0.04 0.06
K1 (ml/ml/min)
Normal breast 0.02±0.01 0.02±0.01 0.59
Breast tumor 0.11±0.05 0.13±0.07 0.41
Nodes 0.18±0.09 0.13±0.12 0.23
Bone metastases 0.16±0.08 0.24±0.13 0.25
Liver metastases 0.26±0.20 0.25±0.10 0.26
K3 (min
−1)
Normal breast 0.02±0.01 0.01±0.01 0.42
Breast tumor 0.05±0.03 0.03±0.02 0.05
Nodes 0.07±0.04 0.05±0.02 0.11
Bone metastases 0.06±0.04 0.05±0.03 0.18
Liver metastases 0.10±0.09 0.03±0.02 0.11
BF (ml/ml/min)
Normal breast 0.04±0.03 0.04±0.02 0.88
Breast tumor 0.43±0.23 0.35±0.15 0.09
Nodes 0.60±0.27 0.21±0.17 0.15
Bone metastases 0.41±0.24 0.51±0.29 0.26
Vd (ml/ml)
Normal breast 0.13±0.06 0.10±0.07 0.95
Breast tumor 0.69±0.17 0.63±0.28 0.29
Nodes 0.73±0.19 0.54±0.29 0.17
Bone metastases 0.67±0.21 0.67±0.30 0.77
MRglu/BF (μmol/ml)
Normal breast 0.17±0.16 0.14±0.08 0.75
Breast tumor 0.31±0.19 0.21±0.03 0.06
Nodes 0.23±0.15 0.32±0.21 0.79
Bone metastases 0.41±0.29 0.26±0.15 0.05
SD Standard deviation, CTh chemotherapy
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PET Parameters vs. Clinical Outcome
Because ten of 11 patients showed disease progression
during clinical follow-up, patients were subdivided further
into those that showed early disease progression (TTP≧
6 months) vs. those with late (TTP96 months) or no
progression. Seven patients showed early disease progres-
sion. In three patients, TTP was longer than 6 months, and
one patient was still in clinical remission at the end of
follow-up.
Mean MRglu/BF was lower in patients with late or no
progression than in patients with early progression (0.24±
0.11 vs. 0.34±0.21), but this difference was not statistically
significant (p=0.21). Similarly, differences between baseline
and post-therapy values of BF, MRglu, and Vd in patients
with early progression vs. patients with late or no progres-
sion were not statistically significant (data not shown).
When assessed on a lesion basis (Fig. 4), however, MRglu
and BF increased only in lesions of patients who progressed
early. In contrast, no increase in MRglu and BF was seen in
any lesion of patients with TTP96 months. In these patients,
MRglu and BF decreased –32%±21% (range −8% to –69%)
and –22%±19% (range –6% to –60%), respectively. No
predictive pattern as to the occurrence of progression could
be found in changes in Vd or MRglu/BF (Fig. 4).
Discussion
The primary aim of this pilot study was to compare early
chemotherapy-induced changes in blood flow and in glucose
metabolism in metastatic breast cancer lesions.
The present study is, to our knowledge, the first to report
BF and Vd values for regional and distant breast cancer
metastases. Baseline MRglu, BF, and Vd were different
among different tumor lesions. MRglu and the associated
microparameters K1 and k3 were highest in liver metastases.
MRglu was lowest (and similar) in breast and node lesions.
Baseline BF values were comparable in breast and bone
lesions, and on average higher in nodes. In contrast, Vd was
comparable among all three lesions.
Mean BF values in breast tumors were higher than
previously reported in patients with (locally advanced) breast
cancer, namely, 0.43±0.23 ml·ml−1·min−1 in the present
study vs. 0.32 ml·ml−1·min−1 [13] and 0.30 ml·ml−1·min−1
[18] in two earlier studies. Interestingly, Wilson et al. [18]
did report a mean tumor BF of 0.42 ml·ml−1·min−1 in a
subset of patients with Mx or M1 disease, comparable with
values in the present study, and higher than values in their
patients with M0 disease (0.24 ml·ml−1·min−1). It is known
that tumor growth, progression, and metastagenicity require
angiogenesis [30, 31]. In fact, microvessel density has been
shown to be significantly higher in breast tumors of patients
with metastases, than in those without [32]. The reason for
the higher BF values in breast tumors of patients with
metastatic disease could be due to this phenomenon,
signifying a change in tumor biology (higher vasculariza-
tion) associated with increased metastatic potential. With a
mean value of 0.41±0.24 ml·ml−1·min−1, BF in bone lesions
was much higher than that reported for normal bone marrow,
namely, 0.11–0.18 ml·ml−1·min−1 [33].
After chemotherapy, correlation between BF and MRglu
increased dramatically for breast lesions, while in bone
lesions, correlation was similar before and after therapy. In
breast lesions, both k3 and K1 contributed to this improve-
ment in correlation, since both showed a significantly higher
correlation with BF after therapy, although this was more
pronounced for k3 (r=0.94 vs. r=0.83, Table 3). This is
partly confirmed by the study by Tseng et al. [34] involving
chemotherapy-treated LABC patients, who suggested that
the phosphorylation step (k3) was responsible for the
improved correlation they observed after chemotherapy.
BF and K1 did not correlate well before therapy (Table 3),
in contrast to findings of Zasadny et al. [19] and Tseng et al.
[34]. Both proposed that BF could possibly be replaced by
K1, at least for some aspects of metabolic analyses. Although
correlation between BF and K1 improved after chemotherapy
Fig. 1. BF (a), Vd (b), and MRglu/BF (c) at baseline (bold
symbols) and after one course of chemotherapy (open
symbols) for normal breast and (metastatic) breast cancer
lesions.
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in the present study (Table 3), as in Tseng et al. [34], it seems
that with the unexplained variance between BF and K1 found
in both studies, BF cannot be reliably replaced by K1.
Vd reflects the amount of tumor tissue that rapidly
exchanges water with blood within the time of the H2
15O
scan [18], and it has been suggested that this represents the
proportion of viable tissue within a tumor [35]. If chemo-
therapy leads to hypo- or hyperperfusion, it will cause a
decrease or increase, respectively, in perfusion, but no
change in blood volume and Vd. If therapy causes vascular
shutdown, this would lead to a reduction in all three
parameters [35]. In breast tumors and nodes, both BF and
Vd decreased after therapy, although to different degrees
(Table 2). This could mean that chemotherapy results in
some degree of vascular shutdown in these lesions. Vd is also
very low in normal breast tissue, however, (see Fig. 1b) so
an alternative explanation for the lower Vd in breast tumors
after chemotherapy could be that values (partially) return to
normal. In contrast, mean BF increased in bone lesions,
while Vd remained unchanged. Therefore, chemotherapy
apparently caused some hyperperfusion in bone metastases.
Mankoff et al. [13] first introduced the MRglu/BF ratio as
a parameter that could predict complete response in LABC
patients and suggested that a high ratio indicates high
glucose extraction. In fact, this ratio is more complex, as it
is proportional to glucose extraction fraction times k3/(k2+
k3). In theory, tumors can increase glucose extraction as a
survival mechanism under conditions of hypoxia or hypo-
perfusion [36]. In the present study, the MRglu/BF ratio of
patients with late (TTP96 months) or no progressive disease
was indeed lower than in those with early progression, but
differences were not statistically significant.
The heterogeneity of response observed in this patient
group is of particular interest (see Fig. 3). Obviously, BF and
MRglu represent two separate physiological processes that
are not necessarily linked. The heterogeneity in some
(responding) bone lesions might partly be explained by the
so-called ‘osteoblastic flare’ phenomenon [37], a paradoxical
increase in tracer uptake after successful response of
osteolytic metastases due to greater radioisotope uptake by
the healing bone. However, the heterogeneous response was
also seen in patients without bone metastases. More
importantly, an increase in either BF or MRglu in any lesion
appeared to be an adverse prognostic sign, regardless of
other, well-responding lesions in the same patient. Mankoff
Fig. 2. Correlation between MRglu and BF for breast (a and b) and bone (c and d) lesions before (a and c) and after (b and d)
one course of chemotherapy.
Table 3. Correlation coefficients between BF, MRglu/BF and micro-
parameters before and after one course of chemotherapy
Parameters Before CTh (r) p After CTh (r) p
Breast tumor
BF and MRglu 0.79 0.02 0.98 0.001
BF and K1 0.43 0.29 0.86 0.03
BF and k3 0.23 0.58 0.94 0.005
Node
BF and MRglu 0.64 0.005 0.62
a 0.14
BF and K1 0.28 0.26 0.63
a 0.13
BF and k3 0.61 0.01 0.14
a 0.77
Bone
BF and MRglu 0.49 0.06 0.50 0.06
BF and K1 0.62 0.03 0.59 0.02
BF and k3 0.52 0.04 0.15 0.59
aOnly seven nodes could be compared on both 18FDG and H2
15O scans
after chemotherapy; see text.
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et al. [14] also found an average rise in BF after 2 months of
chemotherapy in LABC patients who were classified as
clinical or pathological nonresponders. This could mean that
an early increase in either BF or MRglu during chemotherapy
could be used to identify patients who will not respond to
therapy or are at risk for early disease progression. Thirdly,
there are potential implications for the design of future PET-
response monitoring studies involving stage IV breast cancer
patients. Conventionally, according to the RECIST classifi-
cation [20] often used to measure tumor response, only a
limited number of ‘measurable’ target lesions are selected at
baseline (five per organ, ten in total) and used for subsequent
response evaluation. In the light of possible heterogeneous
metabolic response, however, it may be more prudent to
include and follow-up as many target lesions as possible
(within a selected field of view) in order to get a
representative view of the overall tumor response in a
patient. Bone metastases are considered ‘nonmeasurable’ by
the RECIST criteria [20], but both the present study and that
of Stafford et al. [17] suggest that serial quantification of
response in bone metastases is possible. Moreover, there is
some evidence that 18FDG PET can differentiate between
‘active’ and clinically stable bone metastases [38], that PET
is superior (to bone scintigraphy) in detecting osteolytic
bone lesions [39, 40] and that survival in patients with
osteolytic lesions is shorter [40]. As such, uniquely, FDG
PET avidity may be an indirect sign of clinical aggressive-
ness of bone metastases.
This study has a number of limitations. Firstly, the
number of patients was small, and there was variability in
tumor load and treatment. For example, docetaxel and
paclitaxel have known anti-angiogenic effects and would
obviously have a different effect on blood flow compared to
non-anti-angiogenic agents. This could partly explain the
inter-patient response heterogeneity as discussed above, but
does not explain the heterogeneous response observed within
several individual patients.
The purpose of the study was not to investigate the effects
of a specific chemotherapeutic agent on blood flow and
glucose metabolism, however, but to investigate whether
blood flow and glucose metabolism behave differently under
influence of chemotherapy. This was the reason for
including therapies with different mechanisms of action.
Secondly, selection of metastases was restricted by the axial
field of view of the scanner and limited to lesions in the
vicinity of the heart in order to make use of image-derived
arterial input functions. Thus, in some cases, total tumor load
was larger than could be evaluated with this dynamic
scanning protocol.
Conclusion
Simultaneous measurement of changes in tumor perfusion
and glucose metabolism in metastatic breast cancer lesions
during chemotherapy offers the possibility to study different
biological aspects of tumor response to treatment. Chemo-
therapy-induced changes in blood flow and glucose metab-
olism can be markedly heterogeneous even between similar
lesions in the same patient.
Fig. 3. Two examples of heterogeneous response in patient
no. 1 with bone lesions only (a) and in patient no. 9 with
breast tumor, nodes, and bone metastases (b). MRglu and
BF post-chemotherapy are expressed relative to a baseline
value of 100%.
Fig. 4. Percentual changes in MRglu, BF, Vd, and MRglu/BF
ratio for all lesions compared to baseline. Patients with early
disease progression (TTP≧6 months, closed symbols) vs.
late or no progression (open symbols).
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